Clinical Trial Update: Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating efficacy and safety of mepolizumab in subjects with severe hypereosinophilic syndrome has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypereosinophilic Syndrome

Drugs mentioned

• Mepolizumab (mepolizumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hypereosinophilic Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2020-02-21